A PERMANENT INSTITUTION IN A YOUNG STATE.

There is something instructive about the way Queensland’s most significant medical research institution came into being. It did not emerge from the ambitions of a university faculty, nor from the strategic plans of a hospital board. It came, instead, from a single scientist’s close attention to the diseases of a specific landscape — a landscape that, in the decades following federation, was still shaping the bodies and vulnerabilities of those who worked and lived within it. The act of parliament that created the Queensland Institute of Medical Research in 1945 was, in this sense, less a bureaucratic milestone than a recognition: that Queensland’s particular geography demanded a particular kind of knowledge, and that knowledge required a permanent institutional home.

That institution today carries the name QIMR Berghofer Medical Research Institute. It sits at 300 Herston Road in inner Brisbane, a campus of three major buildings embedded in what is now one of Australia’s most concentrated health and research precincts. Its research spans cancer biology, infectious and parasitic disease, mental health genetics, and population health. It employs close to a thousand scientists, students, and support staff. In 2025, it marked its eightieth anniversary — eight decades in which the scope, ambition, and output of the institute have expanded far beyond anything its founders might have anticipated, while remaining anchored to a founding civic logic that has not essentially changed.

To understand what QIMR Berghofer is, and why it matters to Queensland’s civic identity, it helps to begin not with its present capabilities but with the circumstances of its founding. The story that led to the passage of the Queensland Institute of Medical Research Act 1945 is the story of a scientist working at the edge of what was then known, in a state that had good reasons to take infectious disease seriously.

THE DERRICK QUESTION AND THE BIRTH OF AN INSTITUTE.

Dr Edward Derrick was, by the mid-1930s, the Director of the Queensland State Health Department’s Laboratory of Microbiology and Pathology. His work brought him into direct contact with the kinds of illness that the Queensland climate made endemic: conditions that affected meatworkers, cane farmers, and those who spent their lives in the tropics and subtropics north of the Tropic of Capricorn. Among these conditions was a febrile illness of unknown origin that had been observed among abattoir workers in Brisbane since at least 1935. Derrick named it Q fever — the Q standing for “query,” reflecting the unknown nature of its cause — and his subsequent investigations, in collaboration with researchers at the Burnet Institute, eventually led to the identification of the causative organism as the rickettsia Coxiella burnetii. The work was internationally recognised. But it also made something clear to Derrick that was harder to publish in a journal: Queensland needed a permanent, dedicated research facility for exactly this kind of work.

His report to the Queensland Government made that case, and it was persuasive enough. Through his persistence, the Queensland Institute of Medical Research Act was passed by the Queensland Parliament in 1945. The institute it created was explicitly conceived to investigate diseases endemic to Queensland’s climate — not as a general-purpose biomedical facility, but as a direct institutional response to the particular disease burden of a tropical and subtropical state. It was, from the outset, a civic instrument. Research in the public interest, funded by the state, governed by an independent council, and accountable to the people of Queensland through parliament.

Operations began in 1947, with a staff of seven working out of a decommissioned United States Army hut in Victoria Park, adjacent to what was then the Brisbane General Hospital. The contrast with the institute’s present infrastructure could hardly be greater. But there was continuity of purpose even in those provisional surroundings. From the beginning, the institute was directed outward — toward the diseases that were actually afflicting people, in the places where those people actually lived.

TROPICAL FOUNDATIONS AND EARLY DISCOVERIES.

For its first three decades, the institute’s research remained anchored to the infectious disease problems of northern Australia. Between 1951 and 1965, a field station in North Queensland allowed QIMR researchers to investigate outbreaks of leptospirosis, scrub typhus, dengue, and other tropical fevers in the communities where they occurred. This was not laboratory science conducted at a remove from its subject matter; it was research embedded in the epidemiological realities of post-war Queensland, a state still managing the health consequences of its own geography.

That field work produced knowledge that extended well beyond Queensland’s borders. In 1960, QIMR scientists isolated the Murray Valley encephalitis virus from mosquitoes — a significant advance in the understanding of mosquito-borne arboviruses in the region. Three years later, the Ross River virus was identified by researchers working within the same program. These were not minor contributions. Ross River fever became one of the most widely distributed arboviral diseases in Australia, and the original identification work done at QIMR in the early 1960s laid the scientific foundation for all subsequent research into its prevention and treatment.

The institute’s ambitions broadened in step with the growth of biomedical science internationally. During the 1960s, an oncology section was established to investigate the role of viruses in the development of cancer. One project examined cancer cells taken from patients with Burkitt’s lymphoma in Papua New Guinea, finding them infected with the Epstein-Barr virus — a discovery that contributed to the eventual understanding of EBV as a cause of multiple leukaemias and lymphomas. Within years, the same virus was found capable of immortalising white blood cells, a discovery with profound implications for the study of immune cells and their DNA.

This transition — from a strictly tropical-infectious-disease mandate toward broader oncological and virological questions — was not a departure from the institute’s founding logic. It was an extension of it. Queensland’s subtropical climate and high ultraviolet exposure made its population unusually vulnerable to skin cancers, including melanoma. The same geography that had made Q fever and Ross River virus urgent problems also made cancer a Queensland-specific public health concern. The institute was following the evidence, and the evidence was pointing toward the diseases that Queenslanders were actually getting.

GROWTH, GOVERNANCE AND THE HERSTON MOVE.

For thirty years, QIMR operated from temporary premises in Victoria Park — an arrangement that, while serviceable, was never intended to be permanent. In 1977, the institute relocated to new laboratories in the grounds of the Royal Brisbane and Women’s Hospital at Herston. The move to Herston was more than a change of address; it placed the institute in physical proximity to the clinical environment that its research was designed to inform and improve. The logic of co-location — of research adjacent to patient care, of discovery feeding directly into treatment — became a defining principle of what would eventually become the Herston Health Precinct.

In 1988, the Queensland Government amended the QIMR Act to make the institute a statutory authority, reflecting both its growth and its maturing institutional identity. Under Premier Mike Ahern, thirty million dollars was committed to a new purpose-built research facility. Construction of the eleven-storey Bancroft Centre — named in honour of the Bancroft family, whose contributions to Queensland medical research extended back to the nineteenth century — was completed in 1991. The naming was deliberate and meaningful. Dr Joseph Bancroft, who had arrived in Brisbane from England in the 1870s and gone on to discover the parasite Wuchereria bancrofti, was a direct intellectual ancestor of the institute’s founding mission: a scientist who had brought rigorous method to bear on the diseases of a new and medically unfamiliar environment.

The 1990s brought further transformation. A new building for the Cancer Research Centre was made possible by a twenty-million-dollar donation from property developer and philanthropist Clive Berghofer, matched by both federal and state governments. The donation catalysed a wave of cancer research activity. A gene therapy trial for melanoma — one of the first of its kind in the world — was conducted at the Cancer Research Centre for Vaccine Development, demonstrating an immune response in patients. The institute was now conducting work that placed it not merely in the national conversation about medical research, but in a global one.

THE BERGHOFER NAME AND THE WEIGHT OF PHILANTHROPY.

The relationship between the Queensland Institute of Medical Research and Clive Berghofer deepened significantly in August 2013, when Berghofer donated a further fifty-one million dollars to the institute — a gift reported at the time as the largest philanthropic donation by a single individual in Australian history. In recognition of this extraordinary commitment, the institute was renamed QIMR Berghofer Medical Research Institute. A new visual identity was unveiled, the first update to the institute’s logo since 1976.

The significance of the Berghofer gift extends beyond its scale. Private philanthropy of this order directed toward a public research institution creates a particular kind of relationship between civic and private purpose. The gift did not alter the institute’s fundamental character as a statutory authority governed in the public interest; it amplified what was already there. Clive Berghofer, a Toowoomba-born businessman with no scientific training but a profound commitment to the health of Queenslanders, chose to invest in this institution because of what it already was: a serious, productive, place-rooted research organisation with a demonstrated record of turning scientific work into health benefits for real people. The philanthropy recognised value; it did not manufacture it.

The story of how that gift shaped the institute’s trajectory — and what it says about the relationship between private generosity and public science in Queensland — is material that deserves its own close attention, and the institute’s broader philanthropic history is covered in related work on this subject. What matters here is that the renaming in 2013 marked a significant moment in the institute’s identity: the moment at which its civic character and its private benefaction were formally fused into a single name, legible to the public on every building, paper, and publication the institute produces.

WHAT THE INSTITUTE DOES AND WHERE IT DOES IT.

In the present, QIMR Berghofer’s research is organised into four program areas: Cancer Research; Infection and Inflammation; Brain and Mental Health; and Population Health. The breadth of this portfolio reflects eight decades of institutional evolution, but also the genuine complexity of the health challenges that the institute has taken as its province.

The Cancer Research program encompasses work on leukaemia, melanoma, breast, prostate, pancreatic, oesophageal, and colorectal cancers, among others. The Infection and Inflammation program addresses globally significant challenges including malaria, HIV, dengue fever, Group A streptococcus, scabies, and schistosomiasis. The Brain and Mental Health program covers schizophrenia, dementia, Alzheimer’s disease, and related conditions, with particular strength in the genetic epidemiology of psychiatric disorders. The Population Health program takes a broader view of disease risk across communities, including work on skin cancer risk, vitamin D, and the health of Indigenous Australians.

The institute is home to almost a thousand scientists, students, and support staff working across more than sixty state-of-the-art laboratories. Within its campus, QIMR Berghofer maintains facilities that allow it to move research from fundamental discovery through development, scale-up, and manufacture to Phase I and II clinical trials — a rare degree of integration for a single institution. Q-Pharm Pty Limited, which became operational in 2002, is a Phase I clinical trials facility for testing potential therapeutic products in humans. Q-Gen Cell Therapeutics provides capacity for the GMP manufacture of cell-based and molecular therapies. These are not peripheral activities; they are the institutional infrastructure of translation — the machinery by which a research finding becomes a treatment option available to a patient.

The physical setting reinforces this purpose. The Herston Health Precinct co-locates QIMR Berghofer with the Royal Brisbane and Women’s Hospital, the Surgical, Treatment and Rehabilitation Service, and the University of Queensland Centre for Clinical Research. The Queensland University of Technology maintains a healthcare research presence on the broader campus. Pathology Queensland, Genetic Health Queensland, and a range of private companies occupy the precinct or its immediate surrounds. In 2002, a new Indigenous Health Research Program was initiated at QIMR Berghofer to focus specifically on improving health outcomes for Aboriginal and Torres Strait Islander peoples, working in direct collaboration with Indigenous communities. In August 2025, the institute launched its Reflect Reconciliation Action Plan, advancing its public commitment to reconciliation.

RECOGNITION AND RENEWAL IN AN ANNIVERSARY YEAR.

In 2021, QIMR Berghofer received the Queensland Greats Award for its contributions to medicine — a formal recognition by the state of what the institute’s eight decades of work have meant for Queensland and for the wider world. The award placed the institute in the company of individuals and organisations whose contributions to Queensland’s character and capability have been genuinely formative. In 2010, the Queensland Institute of Medical Research had been inducted into the Queensland Business Leaders Hall of Fame, a recognition that, for a scientific institution, spoke to the economic as well as the intellectual value of sustained research excellence.

The year 2025 brought a different kind of renewal. The Queensland Institute of Medical Research Act 2025, introduced to parliament in May of that year, replaced the original 1945 legislation with a modern governance framework. The new act, as described by the institute’s own account of its history, strengthens governance, transparency, and institutional agility — enabling the institute to compete, collaborate, and translate discoveries into health outcomes with greater effectiveness. It also streamlines pathways for commercialising medical innovations, accelerating the journey from laboratory breakthroughs to clinical application.

That a new act was considered necessary after eighty years is itself instructive. The original 1945 legislation was a product of its moment: written for a small institution with a narrow infectious-disease mandate, operating in a state with a much smaller population and a vastly more limited scientific base. The 2025 act is written for an institution that is genuinely global in its reach and ambition, while remaining unmistakably Queensland in its location, its governance, and its fundamental purpose. The legislature that created QIMR in 1945 could not have foreseen what it was making. The legislature that modernised its legal framework in 2025 knew exactly what it was maintaining.

CIVIC IDENTITY AND THE PERMANENCE OF PLACE.

There is a way of reading the history of QIMR Berghofer that emphasises its scientific milestones: the isolation of Ross River virus, the Epstein-Barr research, the melanoma trials, the cancer genomics work. That reading is legitimate and important. The institute’s output in peer-reviewed science, in clinical advances, in trained researchers who have gone on to careers across Australia and the world — these are its most measurable contributions, and they are substantial.

But there is another reading, one that focuses not on individual discoveries but on the institutional fact itself: on what it means for a state to have, at the centre of its capital city, a permanent statutory body whose sole purpose is to investigate the diseases that threaten the health of its people. This institution did not emerge from market forces or from the ambitions of any single university. It was created by parliament, for the public, to address conditions that the public was actually facing. It has been renewed by philanthropy and by legislation, enlarged by successive governments of different political complexions, and recognised by the state it serves as one of its great institutional achievements.

That civic character — the fact of QIMR Berghofer as a public asset, not a commercial one — is something that any serious account of Queensland’s institutional identity needs to grapple with. In a state that has often defined itself through its primary industries, its climate, and its proximity to reef and rainforest, the existence of a world-class biomedical research institute at the heart of Brisbane is not incidental. It reflects a particular understanding of what a government owes its people: not just infrastructure and economic management, but the serious, sustained investment in knowledge that makes it possible to treat, prevent, and ultimately defeat the illnesses that shorten lives and diminish wellbeing.

The onchain civic infrastructure project anchoring Queensland institutions to permanent digital addresses designates qimr.queensland as the namespace for QIMR Berghofer Medical Research Institute — a recognition that the institute’s identity is as much a civic fact as a scientific one, and that civic facts deserve stable, legible addresses in the digital landscape as much as they deserve buildings at Herston Road.

Eight decades is a long time in science. The diseases QIMR Berghofer investigates today — the particular cancer subtypes, the genomic risk factors for psychiatric conditions, the drug-resistant malaria strains, the neurological mechanisms of dementia — bear little surface resemblance to the Q fever and scrub typhus that preoccupied Edward Derrick in the late 1930s. But the underlying logic is identical: a scientist, or a community of scientists, attending closely to the specific disease burden of a specific population, and bringing rigorous method to bear on what they find. That logic was translated into institutional form by a parliamentary act in 1945. Everything that has happened since — the Bancroft Centre, the Berghofer donation, the melanoma research, the clinical trials facility, the 2025 legislative renewal — has been a continuation and an amplification of that original civic act.

Queensland has many institutions it can point to as evidence of its maturity as a polity: its universities, its hospitals, its cultural organisations, its legal and democratic frameworks. QIMR Berghofer belongs in that list. Not because it has produced impressive science, though it has, but because it has remained, for eighty years, exactly what it was designed to be: a permanent public institution, grounded in place, accountable to the people it serves, and directed toward their health and wellbeing. In a world that changes rapidly and often unpredictably, that kind of institutional constancy has its own value — and its own permanence, now recorded at qimr.queensland, as part of the onchain record of what Queensland is and has chosen to build.